Lipocine Announces Positive Top-Line Results in Its Phase 3 Study of LPCN 1021 for Oral Testosterone Replacement Therapy查看全文
$Lipocine(LPCN)$ S-3/A [Amend] Registration statement under Securities Act of 1933 Accession Number: 0001493152-24-015699 Act: 33 Size: 792 KB 网页链接
$Lipocine(LPCN)$ DEF 14A Other definitive proxy statements Accession Number: 0001493152-24-015694 Act: 34 Size: 1 MB 网页链接
$Lipocine(LPCN)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001493152-24-014273 Act: 34 Size: 6 MB 网页链接
$Lipocine(LPCN)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001493152-24-011600 Act: 34 Size: 290 KB 网页链接
$Lipocine(LPCN)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001493152-24-011053 Act: 34 Size: 261 KB 网页链接
$Lipocine(LPCN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001493152-24-009705 Size: 4 KB 网页链接
$Lipocine(LPCN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001493152-24-009707 Size: 4 KB 网页链接
$Lipocine(LPCN)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001493152-24-009283 Act: 34 Size: 14 MB 网页链接
$Lipocine(LPCN)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001493152-24-009127 Act: 34 Size: 9 MB 网页链接
$Lipocine(LPCN)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001493152-24-009128 Act: 34 Size: 406 KB 网页链接